Home/Ternary Therapeutics/Dr Andrew Potterton

DA

Dr Andrew Potterton

CTO and Co-Founder

Ternary Therapeutics

Therapeutic Areas

Inflammation Fibrosis Neuroinflammation

Ternary Therapeutics Pipeline

Drug	Indication	Phase
Molecular Glue Degrader	Neuroinflammation	Pre-clinical
Molecular Glue Activator	Inflammation	Pre-clinical

Leadership Team at Ternary Therapeutics

CEO and Co-Founder

Dr Rosa Cookson

Chemical Biology

Head of Drug Discovery

View full Ternary Therapeutics profile